CannabisNewsBreaks

WednesdayDec 29, 2021 1:06 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Approval from Independent Review Board for DehydraTECH-CBD Human Clinical Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has received Independent Review Board ("IRB") approval for its planned DehydraTECH-CBD human hypertension study HYPER-H21-4; the approval was received earlier than anticipated. The study is designed to "de-risk" outcomes prior to the company’s planned entry into regulatory pathways for the use of DehydraTECH-CBD to treat hypertension and perhaps other forms of cardiovascular disease. The six-week study, which is entirely funded through the existing cash resources, is planned to include 60 volunteers, aged 45 to 70, using three 150 mg doses of DehydraTECH-CBD daily for the duration of the study. Dosing…

Continue Reading

TuesdayDec 28, 2021 1:20 pm

CannabisNewsBreaks – Cannabis Strategic Ventures Inc.’s (NUGS) Farm-to-Sale Model to Potentially Drive Gains in Quality Control, Profitability

Cannabis Strategic Ventures (OTCQB: NUGS) is an emerging leader in the U.S. cannabis marketplace. The company is beginning to deploy its newly acquired licenses, including the opening of its first Los Angeles-based, customer-facing MDRN (Modern) Tree cannabis dispensary, as it takes key steps forward in its strategic plan to implement a farm-to-sale model. “After securing key licensing, we are wasting no time in deploying those assets to launch one of California’s top vertical cannabis models,” stated NUGS CEO Simon Yu. “MDRN Tree will be our factory retail store — our direct interface with our end-market community — where we plan…

Continue Reading

MondayDec 27, 2021 1:57 pm

CannabisNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) Smart Dry Herb Inhaler Providing Consistent, Predictable Results

RYAH Group (CSE: RYAH) develops innovative IoT products that capture powerful data insights and is on a mission to transform patient care using big data and AI to reshape the understanding and uses of plant-based medicines. The company’s devices and data are being used by a rapidly growing number of participants in plant-based clinical trials around the world, including clinical research into the relationship between medical cannabis consumption and cancer treatment, which is in the very early stages. “Two key constraints that have limited the viability of cannabis studies within an oncological setting are the highly variable nature of the…

Continue Reading

MondayDec 27, 2021 12:58 pm

CannabisNewsBreaks – American Cannabis Partners Producing Differentiated, Niche-Market Product

American Cannabis Partners (“ACP”), a sustainable Jamaican experience canna-business innovator, has sought to capitalize on the global affinity for Jamaican cannabis as well as its close links to Jamaica. ACP is employing traditional Jamaican techniques within its cannabis cultivation, harvesting and curing processes. “The methods, in turn, have resulted in a far superior product for the company, as well as faster growth rates, greater production yields, higher THC levels and enhanced terpene bouquets,” explains a recent article. The U.S. cannabis market has the potential to reach an annual value of $115 billion by 2030, from sales of $17.5 billion in…

Continue Reading

ThursdayDec 23, 2021 1:06 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Building World-Class House of Brands

Flora Growth Corp. (NASDAQ: FLGC) recently signed a licensing agreement with Tonino Lamborghini that marked Flora Growth’s entry into the cannabis beverages market. Under the terms of the partnership, FLGC will produce and distribute Tonino Lamborghini-branded cannabis beverages across North America and Colombia. The product line, which will be produced in Florida for initial sale in U.S. states where cannabidiol (“CBD”) ingestibles are legal, will contain CBD and other premium cannabinoids, including cannabigerol (“CBG”). Tonino Lamborghini is a luxury brand operating in the high-end designer products, hotel, beverage and real estate segments. “We are excited to partner with such a…

Continue Reading

ThursdayDec 23, 2021 12:36 pm

CannabisNewsBreaks – Marijuana Company of America Inc. (MCOA) Expanding Reach into New Regions, Leveraging Partnerships to Facilitate Growth

Marijuana Company of America (OTC: MCOA) has taken steps to extend its reach into new regions, including Latin America, and to leverage current strategic partnerships with several companies and its wholly owned subsidiaries to facilitate growth in an industry that continues to expand despite recent setbacks. Much like other industries around the world, the marijuana market was significantly impacted by the COVID-19 pandemic. The global cannabis market, which was valued at $22.1 billion in 2020, is expected to grow at a CAGR of 13.9% during the 2021 to 2026 forecast period. Companies that MCOA has partnered with include Cannabis Global…

Continue Reading

WednesdayDec 22, 2021 2:32 pm

CannabisNewsBreaks – Genius’ Flagship Innovation Revealed as Mystery Cannabis Pipe Smoked on ‘Sex and the City’ Reboot

Viewers noticed an unusual cannabis device being smoked in episodes one and two of the new HBOMax Series, “And Just Like That.” As it turns out, the device is a Genius Pipe that is shown in the premier episode of the “Sex and the City” reboot, where Carrie is clearly envious as Che lights up a sleek flat pipe and takes a hit as they ride an elevator together. In the second episode, Miranda catches her son Brady smoking weed. The same mystery pipe is dropped hard on the ground; however, the apparently sturdy pipe is undamaged and goes back into a pocket. The…

Continue Reading

WednesdayDec 22, 2021 12:25 pm

CannabisNewsBreaks – AmeriCann Inc.’s (ACAN) Massachusetts Cannabis Center Featured on Award-Winning Series

AmeriCann (OTCQB: ACAN), a cannabis company that develops state-of-the-art cultivation, product manufacturing and distribution facilities, today announced that its Massachusetts Cannabis Center was featured on the award-winning series by Dr. Sanjay Gupta on CNN exploring cannabis treatments for autism. “For nearly a decade Dr. Sanjay Gupta’s breakthrough series has shattered myths and introduced the healing properties of cannabis on a global stage,” said AmeriCann CEO Tim Keogh. “We are proud to play a role in helping Dr. Gupta present the considerable benefits that severe autism patients have achieved being treated with cannabis.” To view the full press release, visit https://cnw.fm/fIF9L…

Continue Reading

WednesdayDec 22, 2021 11:46 am

CannabisNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Partners with Avicanna to Launch New Derma-Cosmetic Brand

Red White & Bloom (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, is working with Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) to unveil a new THC-free, CBD derma-cosmetic brand. The first known CBD skincare line to be clinically tested and commercialized across four international markets, Pura H&W will include seven SKUs of proprietary products. The products are formulated using a combination of purified CBD and other synergistic botanical ingredients designed to naturally regulate and nourish the skin. The Pura H&W product line was developed by Avicanna and specific products have undergone clinical trials.…

Continue Reading

TuesdayDec 21, 2021 2:52 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM), Entry into Different Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX) is embarking on new programs as well as extending ongoing ones as it pursues regulatory approvals and entry into different market sectors. In January 2022, the company expects to report blood pressure findings from its third human hypertension study, HYPER-H21-3, building on the successes of the first two human studies that evidenced effective, sustained and safe blood pressure reduction with DehydraTECH-CBD. The company will also be expecting approvals for the protocols around its fourth hypertension study, HYPER-H21-4, which is just one of the many planned studies slated for 2022. “Others include HOR-A22-1, a pharmacokinetic study…

Continue Reading